FIG. 1 Kaplan-Meier curve (PFS and OS)




FIG. 2 Kaplan-Meier curve (PFS and OS) from patients stratified depending on exposure to GC33




FIG. 3 Kaplan-Meier curve (PFS) from patients stratified depending on the number of neutrophil in peripheral blood




FIG. 4 Kaplan-Meier curve (PFS) from patients stratified depending on the number of CD4+ T cell in peripheral blood




FIG. 5 Kaplan-Meier curve (PFS) from patients stratified depending on the number of CD56-/CD16+ NK cell in peripheral blood




FIG. 6 Kaplan-Meier curve (PFS) from patients stratified depending on expression level (MESF) of CD16 on NK cell in peripheral blood




FIG. 7 Kaplan-Meier curve (PFS) from patients stratified depending on baseline *in vitro* ADCC activity (CD16 expression)




FIG. 8 Kaplan-Meier curve (PFS) from patients stratified depending on baseline *in vitro* ADCC activity (CD107a expression)

